Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVoyager Therapeutics Inc

Voyager Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.765 USD -0.06 ( 3.29%)
Last update at 2026-11-11T20:58:00Z
VOLUME
536297
Market Cap
190.40M

Momentum Score

…

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.75
Low
1.84
High
52 Week Price Range
2.94
Low
5.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Voyager Therapeutics develops AAV-based gene therapies targeting serious central nervous system disorders, with a focus on clinical-stage programs for neurodegenerative diseases. Long-term growth drivers include clinical readouts, platform validation, and potential partnerships or approvals that may benefit the company's commercial prospects and make it of interest to investors seeking exposure to neurogene therapy innovation.
The most important investment risks are clinical and regulatory failure, lengthy development timelines that may require additional financing, and manufacturing and competitive challenges that could delay or prevent commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.82
Dividend Yield
-
Revenue TTM
34.46M
Revenue Per Share
0.58
Gross Profit TTM
-81.60M
Debt / Equity
0.19
ROE
-54.09%
Net Debt
-28.80M
ROCE
-52.97%
Diluted EPS TTM
-1.75

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -119.58M -64.34M 133.74M -46.39M -71.20M
Net income -119.72M -65.00M 132.33M -46.41M -66.03M
Selling general administrative 36.44M 35.92M 35.82M 30.98M 37.25M
Gross profit -91.90M 80.00M 245.57M 40.91M 37.41M
Reconciled depreciation 4.06M 4.73M 4.44M 6.19M 5.17M
Ebit -119.58M -64.34M 122.01M -50.84M -73.62M
Ebitda -115.52M -59.61M 126.45M -44.65M -68.45M
Depreciation and amortization 4.06M 4.73M 4.44M 6.19M 5.17M
Non operating income net other - - - 2.65M 2.81M
Operating income -131.84M -83.29M 122.01M -50.84M -73.62M
Other operating expenses 172.22M 163.29M 127.99M 91.74M 111.03M
Interest expense - - - 1.79M 0.39M
Tax provision 0.14M 0.67M 1.41M 0.02M 0.00M
Interest income - - - - 0.33M
Net interest income 10.62M 18.33M 11.72M 1.79M -0.39M
Income tax expense 0.14M 0.67M 1.41M 0.02M -5.17M
Total revenue 40.37M 80.00M 250.01M 40.91M 37.41M
Total operating expenses 39.94M 163.29M 123.55M 91.74M 111.03M
Cost of revenue 132.27M 4.73M 4.44M 6.19M 73.79M
Total other income expense net 12.27M 18.95M 11.72M 4.45M 2.42M
Net income from continuing ops -119.72M -65.00M 132.33M -46.41M -71.20M
Net income applicable to common shares - - - -46.41M -71.20M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 252.28M 393.05M 351.28M 159.36M 193.85M
Other current assets 4.48M 5.63M 4.35M 4.23M 1.70M
Total liab 56.20M 93.29M 114.96M 100.34M 98.80M
Total stockholder equity 196.08M 299.76M 236.32M 59.02M 95.06M
Other current liab 12.10M 14.17M 16.82M 1.37M 2.74M
Common stock 0.06M 0.06M 0.04M 0.04M 0.04M
Capital stock 0.06M 0.06M 0.04M 0.04M 0.04M
Retained earnings -445.90M -326.18M -261.18M -393.51M -347.10M
Other liab - - - 7.45M 9.21M
Other assets - - 0.00M 1.51M 1.78M
Cash 65.30M 71.37M 68.80M 98.96M 117.43M
Total current liabilities 26.54M 49.79M 64.51M 72.59M 50.98M
Current deferred revenue 1.59M 24.39M 42.88M 65.83M 42.10M
Net debt -28.80M -27.64M -48.51M -75.83M -73.25M
Short term debt 7.84M 7.23M 3.20M 2.83M 5.57M
Short long term debt total 36.50M 43.73M 20.29M 23.13M 44.18M
Other stockholder equity 641.89M 626.30M 497.51M 452.71M 442.26M
Property plant equipment - - - 17.86M 21.92M
Total current assets 202.69M 276.81M 319.68M 124.50M 136.70M
Long term investments 5.24M 65.70M - - -
Net tangible assets - - - 59.02M 95.06M
Short term investments 131.15M 195.32M 162.07M 19.89M 15.11M
Net receivables 1.76M 4.49M 84.45M 0.64M 0.75M
Inventory - - 0.00M 0.78M 1.71M
Accounts payable 5.01M 4.00M 1.60M 2.57M 0.57M
Accumulated other comprehensive income 0.03M -0.41M -0.05M -0.22M -0.14M
Common stock total equity - - - 0.04M 0.04M
Retained earnings total equity - - - -393.51M -347.10M
Non currrent assets other 7.98M 2.87M -0.00M 1.51M 1.78M
Non current assets total 49.59M 116.24M 31.60M 34.86M 57.16M
Capital lease obligations 36.50M 43.73M 20.29M 23.13M 44.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 128.04M -94.86M -141.64M -4.85M 67.52M
Change to liabilities - - - -1.16M -3.40M
Total cashflows from investing activities 125.45M -94.86M - -7.34M 65.91M
Total cash from financing activities 0.82M 114.02M 33.65M 1.11M 0.61M
Change to operating activities - - - -5.73M -2.21M
Net income -119.72M -65.00M 132.33M -46.41M -71.20M
Change in cash -6.21M 3.85M -30.16M -18.74M 12.99M
Begin period cash flow 74.24M 70.39M 98.96M 119.21M 106.22M
End period cash flow 68.04M 74.24M 68.80M 100.47M 119.21M
Total cash from operating activities -132.47M -15.31M 77.92M -12.51M -53.52M
Issuance of capital stock 0.00M 112.78M 31.12M 0.00M 0.00M
Depreciation 4.06M 4.73M 4.44M 6.19M 5.17M
Change to inventory - - - - -2.21M
Change to account receivables 0.27M 81.31M -83.23M 0.47M 7.28M
Sale purchase of stock - 19.30M - 0.48M 0.58M
Other cashflows from financing activities - 1.24M 33.65M 1.11M -0.58M
Change to netincome - - - 9.72M 11.32M
Capital expenditures 2.60M 3.52M 3.26M 2.49M 1.61M
Cash flows other operating - - - 19.16M 4.23M
Cash and cash equivalents changes - - - -18.74M 12.99M
Change in working capital -28.76M 34.86M -66.56M 20.47M 3.29M
Stock based compensation 14.79M 14.79M 11.15M 9.34M 11.32M
Other non cash items -2.83M -4.68M 100.78M -2.11M -2.46M
Free cash flow -135.06M -18.83M 74.66M -15.00M -55.13M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VYGR
Voyager Therapeutics Inc		 -0.06
3.29%		 1.76 - 8.44 5.53 1.23 3.09 2.59
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

75 Hayden Avenue, Lexington, MA, United States, 02421

857 259 5340

https://www.voyagertherapeutics.com

141

Name Title Year Born
Mr. Robert W. Hesslein Sr. VP & Gen. Counsel 1953
Mr. G. Andre Turenne Advisor 1974
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. Pres, CEO & Director 1958
Dr. Krystof Bankiewicz M.D., Ph.D. Founder NA
Dr. Guangping Gao Ph.D. Founder NA
Dr. Mark A. Kay M.D., Ph.D. Founder 1958
Dr. Phillip D. Zamore Founder NA
Mr. Peter P. Pfreundschuh CPA Chief Financial Officer 1969
Ms. Robin Swartz Chief Operating Officer 1971
Mr. Todd Carter Ph.D. Chief Science Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…